MedTrace Logo

Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

NCT06050694 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-04-24

No results posted yet for this study

Summary

This is a phase ll study of participants with untreated diffuse large B Cell lymphoma (DLBCL).

Conditions

  • Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

DRUG

glofitamab

Glofitamab 2.5 mg Cycle 3 Day 8 and 10 mg on Day 15 Cycles 3-6

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • John Kuruvilla, FRCPC · University Health Network, Toronto

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-24
Primary Completion
2027-11-30
Completion
2027-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06050694 on ClinicalTrials.gov